According to a Phase I study led by researchers at The University of Texas MD Anderson Cancer Center, published in Nature Medicine, the novel monoclonal antibody linavonkibart has demonstrated the ...

According to a Phase I study led by researchers at The University of Texas MD Anderson Cancer Center, published today in Nature Medicine, the novel monoclonal antibody linavonkibart demonstrated the ...

Star Therapeutics, a late clinical-stage biotechnology company discovering and developing best-in-class antibodies for bleeding disorders and other diseases, today announced that Adam Rosenthal, Ph.D.

Welcome, everyone, to the JPMorgan Healthcare Conference. We are pleased to have with us the Almirall management team here with us today, Carlos Gallardo, Chairman and CEO; Karl Ziegelbauer, CFO; Jon ...

Spanish dermatology specialist Almirall (BME: ALM) is using its appearance at the 44th JP Morgan Healthcare Conference in San ...

RAPT Therapeutics, Inc. is being acquired by GSK plc for $2.2B as ozureprubart targets IgE disorders with 8–12 week dosing.

As we head into the 2026, let's take a look at biotech licensing deals and M&As that were inked in December 2025.

Many clinical trials include a placebo group—participants who receive an inactive treatment—so researchers can compare ...

First-in-class monoclonal antibody agonist programme for inflammation resolution with broad applicability across major chronic inflammatory diseasesEvolution of Nucleome's non-coding genetics ...

What price would you pay for the chance of just a little more quality time with a loved one facing declining cognition from ...

Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and ...